Paris, France – 04-23-2024 – Lovaltech, a Tours-based biotech company pioneering nasally-administered vaccines, announces a €6.8 million financing round. This funding will enable us to accelerate clinical trials of our nasal vaccine against COVID-19, a major promising technology for optimal, universal protection. To know more
